Tumor immunotherapy continues to improve by incorporating the advances made in the field of immunology, which provides the basis for many clinical trials. However, the relative lack of success in the clinic warrants further investigation of strategies, especially cancer vaccines, as vaccines often are the cornerstone of many immunotherapies. This body of work represents two unique vaccine approaches with the common goal of augmenting tumor-specific immune responses.
